ETC-216 for coronary artery disease

Stephen J. Nicholls, Kiyoko Uno, Yu Kataoka, Steven E. Nissen

Research output: Contribution to journalArticle

21 Citations (Scopus)


Introduction: Increasing attention has focused on the role of high-density lipoprotein function as a target for cardiprotection. Apolipoprotein A-IMilano (AIM) involves a single amino-acid mutation of the major wild-type protein carried on high-density lipoprotein (HDL) particles. Early evidence of beneficial activities of AIM has stimulated support in its development as a potential therapy to reduce cardiovascular risk. Areas covered: The importance of HDL as a target and early data supporting the beneficial effects of AIM are reviewed. All clinical studies of AIM found in PubMed are reviewed. Expert opinion: ETC-216 represents a lipid-deplete form of HDL containing recombinant AIM. While early evidence suggests that administration of ETC-216 promotes rapid regression of coronary atherosclerosis, bringing this compound to clinical practice will require further trials that evaluate its impact on cardiovascular events.

Number of pages8
JournalExpert Opinion on Biological Therapy
Issue number3
Publication statusPublished - 1 Mar 2011


  • apoA-I
  • atherosclerosis
  • high-density lipoprotein
  • risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Nicholls, S. J., Uno, K., Kataoka, Y., & Nissen, S. E. (2011). ETC-216 for coronary artery disease. Expert Opinion on Biological Therapy, 11(3), 387-394.